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Abstract
Background and purpose: Foveal changes were reported in aquaporin- 4 antibody 
(AQP4- Ab) seropositive neuromyelitis optica spectrum disorder (NMOSD) patients; how-
ever, it is unclear whether they are independent of optic neuritis (ON), stem from sub-
clinical ON or crossover from ON in fellow eyes. Fovea morphometry and a statistical 
classification approach were used to investigate if foveal changes in NMOSD are inde-
pendent of ON and progressive.
Methods: This was a retrospective longitudinal study of 27 AQP4- IgG + NMOSD patients 
(49 eyes; 15 ON eyes and 34 eyes without a history of ON [NON eyes]), follow- up me-
dian (first and third quartile) 2.32 (1.33– 3.28), and 38 healthy controls (HCs) (76 eyes), 
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INTRODUC TION
Neuromyelitis optica spectrum disorders (NMOSDs) are relapsing 
inflammatory diseases of the central nervous system with a predi-
lection for optic nerves, brainstem and spinal cord [1] The discovery 
of pathogenic antibodies to astrocytic aquaporin- 4 (AQP4) water 
channels [2] in the majority of patients [3,4] has led to NMOSD 
being categorized as a primary astrocytopathy, in which AQP4 anti-
bodies (AQP4- Abs) cause complement- mediated damage to AQP4- 
expressing astrocytes [3]
Aquaporin- 4 antibody seropositive NMOSD is defined by a re-
lapsing course, but without chronic clinical progression or chronic 
lesion activity [5] Acute optic neuritis (ON) is a frequent manifesta-
tion of AQP4- Ab seropositive NMOSD and is typically characterized 
by severe visual impairment [6] posterior involvement of the optic 
nerve on magnetic resonance imaging, severe damage neuropatho-
logically [7] and neuroaxonal loss in the retina measured by optical 
coherence tomography (OCT) [8]
An increasing number of studies have reported retinal changes 
in NMOSD patient eyes with no known history of clinical ON [9– 11] 
This is supported by data from animal models of NMOSD, in which 
rats injected with AQP4- Abs show complement- independent Müller 
cell loss in the retina [12] Müller cells are glial cells that extend longi-
tudinally through the retina [13] and that express AQP4 in end feet 
covering retinal blood vessels [14,15] Müller cell density is high in the 
parafoveal area, but it decreases in the central avascular foveal zone 
[16] To specifically target this area in OCT a fovea morphometry on 
3D macular OCT images was developed, which can reliably describe 
the foveal/parafoveal shape [17] Using this approach, specific foveal 
changes in NMOSD were previously reported, which are distinct to 
changes in multiple sclerosis patients, a disorder also leading to ON 
but without AQP4- Abs [18]
An alternative hypothesis is that foveal changes stem from ON 
attacks that do not reach clinical threshold or from chiasmal cross-
over during an ON in the contralateral eye. Whilst the focus of this 
research has been on the fovea, previous studies also reported some 
degree of neuroaxonal damage in eyes without clinical ON [10] 
When excluding patients with a history of ON, evidence for retinal 
neuroaxonal damage was still found [9] and neuronal loss in the gan-
glion cell layer may even be progressive [10] lending support to this 
hypothesis.
The aim of this study was to longitudinally describe parafoveal 




In this retrospective study of patients and controls followed in two 
longitudinal observational studies in Oxford and Berlin, NMOSD 
AQP4- Ab seropositive patients with no other ophthalmological or 
neurological disease and a minimum of 1 year clinical and OCT fol-
low- up were included. Inclusion criteria were (1) a clinic diagnosis 
of AQP4- Ab seropositive NMOSD according to the 2015 diagnostic 
criteria [19]; (2) follow- up examinations with minimum longitudinal 
clinical and OCT imaging data of 1 year; (3) minimum age of 18 at 
baseline; (4) minimum of 1 year from ON to baseline; (5) macular 
OCT scan characteristics, 61 B- scans with 768 A- scans. Exclusion 
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follow- up median (first and third quartile) 1.95 (1.83– 2.54). The peripapillary retinal nerve 
fibre layer thickness and the volume of combined ganglion cell and inner plexiform layer 
as measures of neuroaxonal damage from ON were determined by optical coherence 
tomography. Nineteen foveal morphometry parameters were extracted from macular op-
tical coherence tomography volume scans. Data were analysed using orthogonal partial 
least squares discriminant analysis and linear mixed effects models.
Results: At baseline, foveal shape was significantly altered in ON eyes and NON eyes 
compared to HCs. Discriminatory analysis showed 81% accuracy distinguishing ON vs. 
HCs and 68% accuracy in NON vs. HCs. NON eyes were distinguished from HCs by fo-
veal shape parameters indicating widening. Orthogonal partial least squares discriminant 
analysis discriminated ON vs. NON with 76% accuracy. In a follow- up of 2.4 (20.85) years, 
no significant time- dependent foveal changes were found.
Conclusion: The parafoveal area is altered in AQP4- Ab seropositive NMOSD patients 
suggesting independent neuroaxonal damage from subclinical ON. Longer follow- ups are 
needed to confirm the stability of the parafoveal structure over time.
K E Y W O R D S
aquaporin- 4 antibodies (AQP4- IgG), foveal morphometry, neuromyelitis optica spectrum disorders 
(NMOSD), optic neuritis, retinal neuroaxonal damage
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criteria were ophthalmological or neurological comorbidities poten-
tially influencing OCT results, insufficient OCT image quality, acute 
ON attacks in the last 12 months or ON attacks during follow- up. 
Data from healthy age and sex matched controls were selected from 
both centres' image databases; longitudinal OCT data for healthy 
controls (HCs) was only available from the Berlin site. A flow diagram 
of the study cohort is presented in Figure 1.
Optical coherence tomography
All participants were scanned on Spectralis spectral domain devices 
(Heidelberg Engineering, Heidelberg, Germany) with automatic 
real- time (ART) function for image averaging. The peripapillary 
retinal nerve fibre layer (pRNFL) was measured with an activated 
eye tracker using 3.4- mm ring scans around the optic nerve (Berlin 
and Oxford: 12°, 1536 A- scans, 1 ≤ ART ≤ 99). Combined ganglion 
cell layer and inner plexiform layer volume (GCIP), total macu-
lar volume (TMV), inner nuclear layer (INL) and retinal nerve fibre 
layer at the macula were calculated as a 3- mm diameter cylinder 
around the fovea for a macular volume scan (Berlin, 25° × 30°, 61 
vertical B- scans, 11 ≤ ART ≤ 18; Oxford, 30° × 25°, 61 vertical B- 
scans, 17 ≤ ART ≤ 22). Foveal thickness (FT) was measured as the 
mean thickness of a 1- mm diameter cylinder around the fovea for 
the macular scan between the internal limiting membrane and the 
Bruch's membrane. Intraretinal semi- automatic segmentation was 
performed by the same experienced rater (FCO) for all data with 
HEYEX software (version 1.10.4.0 with viewing module 1.0.16.0., 
Heidelberg Engineering) to correct segmentation errors and discard 
scans of insufficient quality. OCT data presented in this study follow 
OSCAR- IB quality criteria [20] and APOSTEL recommendations [21]
Fovea morphometry
To characterize the foveal shape, a 3D modelling algorithm was ap-
plied to macular OCT scans, applying parametric modelling of the 
fovea using cubic Bèzier equations for foveal morphometry [17] 
The method extracts foveal measurements such as depth, diameter, 
slope, pit and areas and volumes of different regions (Figure 2a). A 
detailed parameter overview is provided in Appendix A.
Statistical methods
Group differences between AQP4- Ab seropositive NMOSD pa-
tients and HCs were tested by Fisher's exact tests for sex and by 
the Mann– Whitney U test for age. Multivariate analysis was used 
to analyse baseline and longitudinal differences for OCT and fo-
veal shape parameters. Linear mixed effects (LME) models were 
applied to account for inter- eye correlations of monocular meas-
urements. The initial model used for all the parameters was 
‘OCT ~ Age at baseline + Sex + Site + Group, random = ~1|Eye’ for 
baseline and a nested LME model described as ‘OCT ~ Age at base-
line + Sex + Site + Group × time since baseline, random = ~1|Patient/
Eye’ for the longitudinal analysis. From the initial models, simpler 
models were built by discarding not significant fixed effects, to avoid 
overfitting the model.
Group comparisons were established both at baseline and lon-
gitudinally by obtaining estimated marginal means for the mixed 
effects model and contrasts of estimated marginal means were com-
puted of all pairwise comparisons of least squares means.
After this, orthogonal partial least squares discriminant analysis 
(OPLS- DA) was applied to identify the best combination of foveal 
and macular measure to discriminate the NMOSD AQP4- Ab sero-
positive patients from HCs. OPLS- DA is a supervised multivariate 
analysis approach used to investigate the variables that are respon-
sible for class discrimination between disease groups [22] Nineteen 
foveal and six macular parameters from each patient were included 
in the model. In brief, after correction for unequal class sizes, 10- fold 
external cross- validation was performed; this entails splitting the fo-
veal and macular data into a training set (using 90% of data) and a 
test set (using 10% of data) a total of 10 times to ensure that each 
sample appears in the test set exactly once. The test set is applied 
F I G U R E  1  Study cohort and follow- up 
flowchart. Flowchart of participants in 
the cohort study. NMOSD, neuromyelitis 
optica spectrum disorders; AQP4- ab+, 
aquaporin- 4 antibody positive; ON, optic 
neuritis eyes [Colour figure can be viewed 
at wileyonlinelibrary.com]
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to the OPLS- DA model (generated using only the training set) to de-
termine the predictive accuracy on independent (previously unseen) 
data. This process was repeated 100 times to produce 1000 models 
in total. If these models perform better than models produced by 
random class assignments (50%) then separation of the two groups 
has not occurred by chance and the model is statistically significant 
[23,24] To identify the most important foveal/macular parameters 
responsible for the separation between patient groups, variable im-
portance in projection (VIP) scores were generated. A VIP score is 
a measure of a parameter's importance to the OPLS- DA model: the 
higher the VIP score, the more importantly the parameter contrib-
utes towards the separation of patient groups. OPLS- DA was per-
formed using in- house scripts and the ropls package in R software 
[23,25]
Statistical significance was established at p < 0.05. All tests and 
graphical representations were performed in R 3.6.2 with packages 
nlme, ropls, ggplot2 and emmeans.
RESULTS
Cohort overview
Thirty- eight HCs and 27 AQP4- Ab seropositive NMOSD patients 
were included in the analysis (Table 1). Of the AQP4- Ab seropositive 
NMOSD group, 34 eyes never had a history of ON (NON), and 15 
had a history of ON. Four eyes were excluded from the analysis due 
to poor image quality or technical issues, one eye due to amblyopia. 
There were no significant differences between the HCs and the 
NMOSD group in the baseline demographic.
Group differences at baseline analysed using multivariate LME 
models with estimated marginal means adjusted for age at baseline, 
sex and site whilst accounting for inter- eye correlations are presented 
in detail in Table 2. As expected, the models showed significant thin-
ning in pRNFL, GCIP, TMV and retinal nerve fibre layer at the macula 
in ON eyes compared to HC eyes, suggesting profound neuroaxonal 
damage. NON vs. HC eyes showed significantly thinner GCIP, TMV, 
INL and FT, but changes were less severe than in the ON eyes (Table 2).
Foveal changes
Fovea morphometry quantifies several metrics of the fovea 
(Figure 2a). Visually, ON- related changes in the fovea/parafoveal 
area appear as flattened, whereas NON changes appear to be wid-
ened, already suggesting different mechanisms causing the change 
(Figure 2b,c). Lower values for ON vs. HC eyes were found in the 
following parameters: average pit depth, average rim height, aver-
age rim diameter, rim disc area, major and minor rim disc length, pit 
volume and average maximum pit slope degree. ON vs. NON eyes 
showed significantly lower values for average pit depth, average 
rim height, average rim diameter, minor slope disc length, slope disc 
area, rim disc area, major and minor rim disc length, pit volume and 
average maximum pit slope degree. NON vs. HC eyes showed sig-
nificantly lower values for average rim height and higher values for 
minor slope disc length, slope disc area, average slope disc diameter, 
F I G U R E  2  Foveal changes in NMOSD. (a) Cross- sectional, 2D illustration on a central B- scan of foveal region parameters extracted with 
the CuBe algorithm [17]. (b) Eyes with a history of ON (ON eyes) and (c) eyes without a history of ON (NON eyes). Both horizontal dashed 
lines in (b) and (c) refer to the central foveal thickness distance, defined as the minimum height of the fovea at the centre of the pit. ON, optic 
neuritis; NON, non- optic neuritis [Colour figure can be viewed at wileyonlinelibrary.com]
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pit disc area, average pit flat disc diameter, and major and minor pit 
flat disc length (Table 2 and Appendix A, Figure A2).
Discriminatory analysis
Orthogonal partial least squares discriminant analysis identifies a 
linear combination of measures to separate two groups, with the 
aim of being able to classify individual patients. This method reduces 
the weight of tightly correlated values that do not give additional 
benefit. OPLS- DA was employed as a supervised statistical method 
to discriminate ON from HCs, ON vs. NON and NON eyes from 
HCs. The mean predictive accuracy of the OPLS- DA models distin-
guishing ON vs. HC eyes was 81.16% ± 5.39% (p < 0.0001), whilst 
the mean predictive accuracies of the OPLS- DA models separat-
ing ON vs. NON eyes and ON eyes vs. HCs were 76.48% ± 5.33% 
(p < 0.0001) and 67.71% ± 4.77% (p < 0.0001) respectively (Figure 3).
Importantly, the top nine most discriminatory variables con-
tributing to the separation of ON eyes from HC and NON eyes 
are pRNFL, GCIP, rim volume, major and minor rim disc length, 
average rim diameter, rim disc area, average pit depth and aver-
age rim height. In the case of the separation between NON eyes 
and HCs, the top nine most discriminatory variables were TMV, 
average rim height, GCIP, average pit flat disc diameter, major 
and minor pit flat disc length, pit disc area, INL and FT (Figure 3). 
The selection of largely different morphometrical factors in ON 
and NON eyes clearly suggest that, whilst NON eyes show some 
evidence of neuroaxonal damage, this damage cannot explain 
the foveal shape changes. The variables that better describe the 
difference between HC and NON eyes are not at the retinal or 
peripapillary level but at foveal level, indicating an unlikely ef-
fect of a subclinical ON and/or a chiasmal crossover effect from 





Number of participants 38 12a  21a 
Number of eyes 76 15b  34b 
Sex
Female n (%) 27 (74%) 10 (83%) 20 (95%)
Age at baseline (years)
Median (1st−3rd 
quartile)









Not available 2 (17%) 3 (14%)
Asian n (%) 1 (8%) 2 (10%)
Caucasian n (%) 8 (67%) 16 (76%)




Not applicable 1.16 (0.39−3.70) 1.90 (0.54– 5.80)c 
Time from last ON (years)
Median (1st−3rd 
quartile)
4.21 (1.94– 9.27) 3.66 (2.15– 8.35)c 
Note: Age and sex group differences between HCs and NMOSD patients were not significant 
(Fisher's exact tests for sex, estimate 4.37, p = 0.1020; Mann– Whitney test for age, estimate 3.19, 
p = 0.3796; follow- up time, estimate −0.33, p = 0.17).
Abbreviations: F/U, follow- up; HCs, healthy controls; NMOSD, neuromyelitis optica spectrum 
disorder; NON, non- optic neuritis; ON, optic neuritis.
aSix patients with bilateral ON, six patients with unilateral ON and 15 patients with no history of 
ON. ON = 6 + 6 and NON = 6 + 15. 
bEyes counted after the exclusion of five eyes. 
cBased on unilateral ON eyes. 
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Longitudinal changes
After OPLS- DA indicated that foveal shape changes in NON eyes are 
unlikely to be attributable to neuroaxonal damage to the optic nerve, 
potential longitudinal changes were then investigated. The analysis 
was limited on NON eyes to not overlay ON- unrelated changes with 
potential changes from ON. Annualized changes from baseline to 
last follow- up for the NON eyes are summarized in Table 3. In sum-
mary, longitudinal analysis using LME models identified no signifi-
cant changes in any of the foveal parameters at follow- up compared 
to baseline (Table 3). Standard ring scan and macular parameters also 
did not change significantly in comparison to HCs (not shown).
DISCUSSION
Our study provides evidence that the parafoveal area, which is rich 
in AQP4- expressing Müller cells, is altered in AQP4- Ab seropositive 
NMOSD patients who never experienced clinical ON, and suggests 
that these changes are likely to be independent of neuroaxonal dam-
age from subclinical ON, as macular and peripapillary layers were 
not affected in this subset. No evidence was found that these foveal 
changes are progressive in a longitudinal follow- up.
Neuroaxonal damage and foveal/parafoveal changes 
from optic neuritis
Optic neuritis causes neuroaxonal damage in NMOSD, and this dam-
age is reflected by pRNFL thickness loss reflecting axonal damage 
and GCIP loss reflecting neuronal ganglion cell loss [9,10,26,27] ON 
in NMOSD typically affects posterior segments of the optic nerve, 
often with involvement of the optic chiasm [28]. Consequently, in 
some cases, inflammatory activity due to chiasmal crossover fibres 
from an ON eye may have partial involvement of the contralateral 
side, which may be overlooked in clinical assessment [29]. Our study 
shows that ON also leads to foveal changes, which can best be de-
scribed as flattening of the parafoveal ring: OPLS- DA selected pri-
marily parameters of neuroaxonal damage (pRNFL, GCIP) as well as 
parameters describing the volume and flatness of the fovea, namely 
a decrease in rim volume, major rim disc length, average rim diam-
eter, rim disc area and others.
Are foveal changes independent of optic neuropathy?
Eyes without a history of ON also showed significant GCIP but not 
pRNFL loss in our study, which is in line with previous studies show-
ing ON- independent retinal changes in NMOSD [9,11] This could be 
explained by the fact that GCIP measurements were performed in 
the parafoveal area, whilst pRNFL reflects the neuroaxonal content 
of the whole eye. Hence, pRNFL measures may not be as proportion-








































































































































































































































































































































































































































































































































































































































































































pronounced than in ON eyes. In a previous study potential progres-
sive GCIP loss in NMOSD patients was reported regardless of ON 
[10] Previously, FT changes on OCT in NMOSD AQP4- Ab seroposi-
tive patients were also reported [9,11]. Fovea morphometry changes 
were also identified not only comparing against HCs but also when 
compared to multiple sclerosis patients [18]. Here it is shown that, 
in contrast to ON eyes, the fovea of NON eyes was characterized 
by wider pits and more pronounced slopes, best described as fo-
veal widening. OPLS- DA selected parameters TMV, average rim 
height, average pit flat disc diameter, minor pit flat disc length, pit 
disc area and others as best discriminatory against HCs. Importantly, 
OPLS- DA selected parameters differed significantly between ON 
and NON eyes, lending strong support to the hypothesis that the 
observed foveal changes in NON eyes are not caused by neuroaxonal 
damage to the optic nerve.
Ours and previous clinical studies did not address the under-
lying aetiology of foveal involvement in AQP4- Ab seropositive 
NMOSD. The parafoveal area is rich in Müller cells, the princi-
pal astrocytic glia of the retina, which express AQP4 in their end 
feet adjacent to retinal vessels [30]. In an animal model of retinal 
damage in NMOSD, AQP4- Ab injection into the vitreous resulted 
in reactive changes and loss of Müller cells without comple-
ment activation [12]. Previous studies have demonstrated lack of 
complement reactivity in the area postrema [31] this could also 
be the case in the retina, where AQP4- Ab would still bind the 
retinal AQP4- expressing cells but would fail to activate the com-
plement, and therefore would not cause mediated damage in the 
retinal cell integrity but still would make the changes in the foveal 
morphometry.
Longitudinal observations
In a previous study progressive GCIP loss in AQP4- Ab seropositive 
NMOSD regardless of ON was reported [10]. In contrast, in the current 
study no evidence for overt progressiveness of foveal shape changes in 
NON eyes was found. Given the sample size limitation of this study, it 
is unclear whether it was simply underpowered or whether changes to 
the fovea are indeed not progressive. Interestingly, OPLS- DA selected 
GCIP but not pRNFL as one of the strongest parameters discriminating 
NON eyes from HCs. It is possible that GCIP changes reflect a neu-
rodegenerative reaction of ganglion cells to Müller cell affection, It is 
possible that GCIP changes reflect a neurodegenerative reaction of 
ganglion cells to Müller cell affection. The discrepancy between pRNFL 
and GCIP differences in NON eyes is interesting and warrants further 
investigation. Future studies with greater sample size and higher power 
F I G U R E  3  OPLS- DA results. (ai) OPLS- DA, ON vs. HC eyes comparison (accuracy 81.16%); (aii) OPLS- DA, ON vs. HC eyes model 
validation; (aiii) VIP scores from all parameters used in the model for each comparison; (aiv) values of the most important parameters for 
ON vs. HC eyes. (bi) OPLS- DA, ON vs. NON eyes comparison (accuracy 76.48%); (bii) OPLS- DA, ON vs. NON eyes model validation; (biii) 
VIP scores from all parameters used in the model for each comparison; (biv) values of the most important parameters for ON vs. NON 
eyes. (ci) OPLS- DA, NON vs. HC eyes comparison (accuracy 67.71%); (cii) OPLS- DA, NON vs. HC eyes model validation; (ciii) VIP scores 
from all parameters used in the model for each comparison; (civ) values of the most important parameters for NON vs. HC eyes. OPLS- DA, 
orthogonal partial least squares discriminatory analysis; VIP, variable importance in projection; ON, optic neuritis; NON, non- optic neuritis; 
HC, healthy control; pRNFL, peripapillar retinal nerve fibre layer; GCIP, ganglion cell and inner plexiform layer volume; INL, inner nuclear 
layer; FT, foveal thickness [Colour figure can be viewed at wileyonlinelibrary.com]
(a) (b) (c)
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are required to address this. The annual changes reported in this study, 
albeit not significant, may serve as a basis for sample size calculations.
Functional relevance
The fovea is the most important region for functional vision in the 
retina [32]. Due to the high concentration of cones, the fovea is re-
sponsible for central vision and involved in high- resolution image 
formation [33]. ON in NMOSD is associated with often severe visual 
function loss [6]. A recent study found that patients with AQP4- Ab 
seropositive NMOSD had worse visual outcomes compared to mul-
tiple sclerosis patients and patients with myelin oligodendrocyte 
glycoprotein antibody seropositive disease in relation to their actual 
ganglion cell loss [34]. Further studies are warranted to confirm the 
clinical relevance and to identify potential avenues for symptomatic 
treatment.
Relevance for other central nervous system areas
Whilst our findings are limited to the retina, the observation that there 
may be subtle AQP4- related damage in NMOSD is also relevant for 
other central nervous system areas. Secondary symptoms in NMOSD 
like cognitive dysfunction [35] fatigue [36] pain [37] and mood disor-
ders [38] are yet mostly unexplained. Imaging studies have so far been 
inconclusive regarding focal damage to brain structures in NMOSD, 
Imaging studies have so far been inconclusive regarding focal damage 
to brain structures in NMOSD happening outside of attack- related 
areas or potentially caused by a secondary axonal or transsynaptic 
TA B L E  3  Annualized foveal changes
NMOSD- NON NMOSD- NON F/U vs baseline
Annualized change, mean (SD) B (SE) p value
Macular parameters
pRNFL (μm) −0.611 ± 1.85 −0.11563 (0.276813 0.6767
GCIP (mm3) −0.009 ± 0.0044 −0.0007202 (0.000816) 0.3788
TMV (mm3) −0.004 ± 0.013 −0.0028363 (0.002249) 0.2090
INL (mm3) 0.003 ± 0.001 −0.00044411 (0.000955) 0.6427
FT (μm) −0.43 ± 2.19 −0.61538 (0.429695) 0.1538
RNFL (mm3) −0.0003 ± 0.006 −0.00122806 (0.000881) 0.1653
Foveal parameters
Average pit depth (mm) 0.00012 ± 0.002 0.0004 (0.0004) 0.3149
Central foveal thickness (mm) −0.0005 ± 0.0001 −0.0004 (0.0004) 0.3891
Average rim height (mm) −0.00038 ± 0.0023 −0.0000040 (0.00039) 0.9918
Average rim diameter (mm) −0.00088 ± 0.01 −0.00059 (0.002) 0.8039
Rim disc area (mm2) −0.0029 ± 0.04 −0.001 (0.007) 0.8040
Major rim disc length (mm) 2.38 E- 05 ± 0.009 0.0000439 (0.0013) 0.9746
Minor rim disc length (mm) −0.0009 ± 0.007 −0.00067 (0.0016) 0.6194
Major slope disc length (mm) −0.001 ± 0.005 −0.001 (0.0008) 0.157
Minor slope disc length (mm) −0.001 ± 0.004 −0.00017 (0.0006) 0.803
Slope disc area (mm2) −0.01 ± 0.026 −0.004 (0.004) 0.35
Average slope disc diameter (mm) −0.006 ± 0.02 −0.002 (0.003) 0.49
Pit disc area (mm2) −0.0002 ± 0.002 −0.0002 (0.0006) 0.6445
Average pit flat disc diameter (mm) −0.0008537 ± 0.006 −0.001 (0.00146) 0.4528
Major pit flat disc length (mm) −7.97E−05 ± 0.0004 −0.00008 (0.00011) 0.4782
Minor pit flat disc length (mm) 1.25 E- 05 ± 0.0005 −0.000016 (0.00008) 0.8469
Rim volume (mm3) 0.000333 ± 0.017 0.00010 (0.0030) 0.9721
Pit volume (mm3) −0.0020 ± 0.008 −0.0003 (0.001) 0.77
Inner rim volume (mm3) 0.00022 ± 0.002 −0.00002 (0.0004) 0.96
Average maximum pit slope degree (º) 0.0034 ± 0.41 −0.041 (0.079) 0.599
Note: Significant p values are shown in bold. Maximum likelihood was used for the estimation of p values.
Abbreviations: B, estimate; FT, foveal thickness; F/U, follow- up; GCIP, combined ganglion cell and inner plexiform layer volume; INL, inner nuclear 
layer; NMOSD- NON, neuromyelitis optica spectrum disease eyes with no history of optic neuritis; pRNFL, peripapillary retinal nerve fibre layer; SE, 
standard error; TMV, total macular volume.
    | 2289NON-­PROGRESSIVE­FOVEAL­CHANGES­IN­NMOSD-­AQP4
neurodegeneration [39– 41]. A recent independent study has identified 
the nucleus accumbens as a potentially interesting target with func-
tional relevance of AQP4- expressing cells for neural plasticity [42].
Limitations and strengths
An important limitation of our study is the small number of NON 
eyes, which prevents us from separately analysing patients with 
contralateral ON and those never having ON. Additionally, most pa-
tients presenting with an acute long extensive transverse myelitis 
and no visual symptoms will not have extensive visual and OCT test-
ing to investigate subtle ON. A recent publication [43] investigating 
latency delay and amplitude reduction in visual evoked potentials in 
patients with no history of ON suggests that attack- unrelated sub-
clinical disease activity may be happening in the visual system; one 
of the limitations of this study is the lack of visual evoked potential 
data that could shed light on how this process happens.
A major strength of this paper is the use of a novel paramet-
ric modelling of the 3D foveal shape using cubic Bèzier equations 
[17]. This has allowed us to describe the fovea and parafoveal area 
in an objective and reproducible way. Our cohort, constituted only 
of AQP4- Ab seropositive patients, sets the first step on clinical 
significance ensuring the examination of only one disease process. 
Further, our results suggest that foveal morphometry may offer clin-
ical diagnostic utility. However, broad application would require fur-
ther validation across alternative platforms and protocols.
CONCLUSION
In summary, evidence is provided that the fovea is wider in NON 
eyes in patients with NMOSD, whereas ON eyes typically present 
with a flatter fovea compared to HCs and NON eyes. Discriminatory 
analysis strongly suggests that changes in NON eyes are not caused 
by subclinical optic neuropathy or ON. Our study supports a model 
in which AQP4- Abs affect antigen- expressing glial cells in NMOSD, 
in this case Müller cells, without complement involvement. This has 
relevance for the pathological understanding of NMOSD as well as 
potential clinical implications.
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APPENDIX A
FOVE A MORPHOME TRY
The fovea morphometry method is described in detail by Yadav et 
al. [17]. Fovea morphometry characterizes the foveal and parafoveal 
region by 19 parameters. The method first flattens the inner limiting 
membrane (ILM) surface according to Bruch's membrane as the refer-
ence (reference plane) and then radially reconstructs the ILM surface, 
from the centre of the fovea up to the points with maximum heights 
which are called rim points, using cubic Bèzier polynomials. Based on 
the reconstructed ILM surface and the reference plane, foveal mor-
phometry parameters are defined. Twelve parameters are defined as 
area, average diameter, major length (the length in the dominant direc-
tion) and minor length (the length in the second dominant direction, 
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perpendicular to the dominant direction) of three different surfaces: 
pit flat disc, a surface that captures the flatness of the foveal pit; slope 
disc, a surface that connects points with maximum slope; and rim disc, 
a surface that connects rim points. In addition to the parameters de-
scribing the defined surfaces, there are several other parameters de-
scribing the fovea: average pit depth, average height of the points on 
the pit flat disc; central foveal thickness, minimum thickness of the 
fovea; average rim height, average height of rim points; rim volume, 
volume between the ILM surface and the reference plane limited to 
rim points; inner rim volume, similar to rim volume but limited to 1- mm 
diameter around the centre of the fovea; pit volume, volume between 
the ILM surface and the rim disc; and average maximum pit slope, aver-
age slope of points with maximum slope. Figure A1 shows an overview 
of the fovea morphometry method.
F I G U R E  A 1  3D representation of the foveal shape. [Colour figure can be viewed at wileyonlinelibrary.com]
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F I G U R E  A 2  Box plots of disc and macular baseline OCT and foveal data where there are significant differences between at least one 
group: (a) peripapillary retinal nerve fibre layer (pRNFL) at the disc; (b) combined ganglion cell and inner plexiform layer volume (GCIP); (c) 
total macular volume (TMV); (d) inner nuclear layer (INL); (e) foveal thickness (FT); (f) retinal nerve fibre layer at the macula (mRNFL); (g) 
average pit depth; (h) average rim height; (i) average rim diameter; (j) rim disc area; (k) slope disc area; (l) average slope disc diameter; (m) pit 
disc area; (n) average pit flat disc diameter; (o) pit volume; (p) average maximum pit slope degree. The boxplots show the median and 25th 
and 75th percentiles [Colour figure can be viewed at wileyonlinelibrary.com]
